James E Galvin

Summary

Affiliation: New York University School of Medicine
Country: USA

Publications

  1. doi request reprint Practical guidelines for the recognition and diagnosis of dementia
    James E Galvin
    Center of Excellence for Brain Aging, New York University Langone School of Medicine, New York, NY 10016, USA
    J Am Board Fam Med 25:367-82. 2012
  2. pmc Improving physician awareness of Alzheimer disease and enhancing recruitment: the Clinician Partners Program
    James E Galvin
    Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO, USA
    Alzheimer Dis Assoc Disord 26:61-7. 2012
  3. pmc Lewy body dementia: the caregiver experience of clinical care
    James E Galvin
    Department of Neurology, New York University Langone School of Medicine, New York, NY 10016, USA
    Parkinsonism Relat Disord 16:388-92. 2010
  4. pmc Relationship of dementia screening tests with biomarkers of Alzheimer's disease
    James E Galvin
    Alzheimer s Disease Research Centre, Washington University, St Louis, MO 63108, USA
    Brain 133:3290-300. 2010
  5. pmc Dementia screening, biomarkers and protein misfolding: Implications for public health and diagnosis
    James E Galvin
    Center of Excellence on Brain Aging, Department of Neurology, New York University Langone Medical Center, New York, NY, USA
    Prion 5:16-21. 2011
  6. pmc Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease
    J E Galvin
    Center of Excellence on Brain Aging, New York University Langone School of Medicine, 145 East 32nd St, Second Floor, New York, NY 10016, USA
    Neurology 76:1797-803. 2011
  7. ncbi request reprint Clinical phenotype of Parkinson disease dementia
    James E Galvin
    Department of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
    Neurology 67:1605-11. 2006
  8. doi request reprint Capgras syndrome in Dementia with Lewy Bodies
    Papan Thaipisuttikul
    Comprehensive Center on Brain Aging, Alzheimer Disease Center, New York University Langone Medical Center, New York, NY, USA
    Int Psychogeriatr 25:843-9. 2013
  9. doi request reprint Guidelines for the management of cognitive and behavioral problems in dementia
    Carl H Sadowsky
    Division of Neurology, Nova Southeastern University, Fort Lauderdale, FL, USA
    J Am Board Fam Med 25:350-66. 2012
  10. pmc Mild physical impairment predicts future diagnosis of dementia of the Alzheimer's type
    Consuelo H Wilkins
    Division of Geriatrics and Nutritional Science, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    J Am Geriatr Soc 61:1055-9. 2013

Detail Information

Publications41

  1. doi request reprint Practical guidelines for the recognition and diagnosis of dementia
    James E Galvin
    Center of Excellence for Brain Aging, New York University Langone School of Medicine, New York, NY 10016, USA
    J Am Board Fam Med 25:367-82. 2012
    ..An AD diagnostic algorithm is provided, with clearly defined steps for screening and diagnosing AD and assessing daily functioning, behavioral symptoms, and caregiver status...
  2. pmc Improving physician awareness of Alzheimer disease and enhancing recruitment: the Clinician Partners Program
    James E Galvin
    Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO, USA
    Alzheimer Dis Assoc Disord 26:61-7. 2012
    ....
  3. pmc Lewy body dementia: the caregiver experience of clinical care
    James E Galvin
    Department of Neurology, New York University Langone School of Medicine, New York, NY 10016, USA
    Parkinsonism Relat Disord 16:388-92. 2010
    ..Lewy body dementia (LBD) is the second most common cause of dementia, however, little is known about how the clinical diagnosis of LBD is obtained in the community or the caregiver experience while seeking the diagnosis...
  4. pmc Relationship of dementia screening tests with biomarkers of Alzheimer's disease
    James E Galvin
    Alzheimer s Disease Research Centre, Washington University, St Louis, MO 63108, USA
    Brain 133:3290-300. 2010
    ....
  5. pmc Dementia screening, biomarkers and protein misfolding: Implications for public health and diagnosis
    James E Galvin
    Center of Excellence on Brain Aging, Department of Neurology, New York University Langone Medical Center, New York, NY, USA
    Prion 5:16-21. 2011
    ..Multi-center trials are now investigating whether imaging and/or cerebrospinal fluid (CSF) biomarker candidates can be used as outcome measures for use in phase III clinical trials for AD...
  6. pmc Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease
    J E Galvin
    Center of Excellence on Brain Aging, New York University Langone School of Medicine, 145 East 32nd St, Second Floor, New York, NY 10016, USA
    Neurology 76:1797-803. 2011
    ..We performed resting state blood oxygen level-dependent (BOLD) functional connectivity MRI (fcMRI) to determine whether there were differences between AD and DLB...
  7. ncbi request reprint Clinical phenotype of Parkinson disease dementia
    James E Galvin
    Department of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
    Neurology 67:1605-11. 2006
    ..To determine which clinical features best characterize Parkinson disease dementia (PDD), compared with Alzheimer disease (AD) and dementia with Lewy bodies (DLB), and to determine the pathologic basis for PDD...
  8. doi request reprint Capgras syndrome in Dementia with Lewy Bodies
    Papan Thaipisuttikul
    Comprehensive Center on Brain Aging, Alzheimer Disease Center, New York University Langone Medical Center, New York, NY, USA
    Int Psychogeriatr 25:843-9. 2013
    ..We reviewed clinical characteristics of Dementia with Lewy Bodies (DLB) patients with Capgras syndrome compared to those without Capgras...
  9. doi request reprint Guidelines for the management of cognitive and behavioral problems in dementia
    Carl H Sadowsky
    Division of Neurology, Nova Southeastern University, Fort Lauderdale, FL, USA
    J Am Board Fam Med 25:350-66. 2012
    ..Looking forward, there are a number of therapies in development aimed at modifying the disease course; these include amyloid-lowering drugs, τ-based and neuroprotective approaches, acetylcholine agonists, and mitochondrial inhibitors...
  10. pmc Mild physical impairment predicts future diagnosis of dementia of the Alzheimer's type
    Consuelo H Wilkins
    Division of Geriatrics and Nutritional Science, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    J Am Geriatr Soc 61:1055-9. 2013
    ..To determine whether mildly impaired physical function (based on performance-based assessment) is associated with development of dementia of the Alzheimer's type (DAT) in cognitively normal older adults...
  11. pmc Lewy body dementia: caregiver burden and unmet needs
    James E Galvin
    Department of Neurology, Washington University, St Louis, MO, USA
    Alzheimer Dis Assoc Disord 24:177-81. 2010
    ..Community resources such as the Lewy Body Dementia Association may serve this end, while also providing practical information and support for caregivers...
  12. pmc The "portable" CDR: translating the clinical dementia rating interview into a PDA format
    James E Galvin
    Alzheimer Disease Research Center, Washington University School of Medicine, 4488 ForestPark, Suite 130, St Louis, MO 63108, USA
    Alzheimer Dis Assoc Disord 23:44-9. 2009
    ....
  13. pmc Four sensitive screening tools to detect cognitive dysfunction in geriatric emergency department patients: brief Alzheimer's Screen, Short Blessed Test, Ottawa 3DY, and the caregiver-completed AD8
    Christopher R Carpenter
    Division of Emergency Medicine, Washington University in St Louis School of Medicine, MO, USA
    Acad Emerg Med 18:374-84. 2011
    ..While multiple brief screening instruments have been derived, ED validation trials have not previously demonstrated tools that are appropriately sensitive for clinical use...
  14. ncbi request reprint Expression profiling in the aging brain: a perspective
    James E Galvin
    Department of Neurology, Anatomy and Neurobiology, Washington University School of Medicine, St Louis, MO 63108, USA
    Ageing Res Rev 4:529-47. 2005
    ....
  15. pmc Psychosocial determinants of intention to screen for Alzheimer's disease
    James E Galvin
    Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
    Alzheimers Dement 4:353-60. 2008
    ..There is little information about how receptive older adults are to discuss memory problems with healthcare providers. Here we test the psychosocial factors explaining older adults' intention to undergo screening for Alzheimer disease (AD)...
  16. pmc Effect of cognitive fluctuation on neuropsychological performance in aging and dementia
    Adriana Escandon
    Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
    Neurology 74:210-7. 2010
    ..Fluctuations are a core feature of dementia with Lewy bodies, but the impact of fluctuations in healthy brain aging and Alzheimer disease (AD) are unknown...
  17. ncbi request reprint Verbal and visuospatial deficits in dementia with Lewy bodies
    David K Johnson
    Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
    Neurology 65:1232-8. 2005
    ..To investigate the cognitive decline in dementia with Lewy bodies (DLBs) and characterize the contribution of Lewy bodies (LBs) to cognitive impairment in the presence of concurrent Alzheimer disease (AD)...
  18. ncbi request reprint Patient's rating of cognitive ability: using the AD8, a brief informant interview, as a self-rating tool to detect dementia
    James E Galvin
    Department of Neurology, Washington University School of Medicine, St Louis, Missouri, USA
    Arch Neurol 64:725-30. 2007
    ..To test the ability of patients to rate their own cognitive ability using the AD8 compared with informant and clinician ratings of cognitive status...
  19. ncbi request reprint Evaluation of cognitive impairment in older adults: combining brief informant and performance measures
    James E Galvin
    Department of Neurology, Washington University, St Louis, Missouri 63108, USA
    Arch Neurol 64:718-24. 2007
    ..To combine the AD8, a brief informant interview, with performance measures to develop a brief screening tool to improve detection of cognitive impairment and dementia in general practice...
  20. ncbi request reprint Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease
    Monique M Williams
    Department of Medicine, Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park, Suite 130, St Louis, MO 63108, USA
    Neurology 67:1935-41. 2006
    ..To determine whether dementia with Lewy bodies (DLB) progresses more rapidly than Alzheimer disease (AD)...
  21. ncbi request reprint Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study
    James E Galvin
    Department of Neurology, Alzheimer s Disease Research Center, School of Medicine, Washington University, St Louis, MO 63108, USA
    Arch Neurol 62:758-65. 2005
    ..To understand the earliest signs of cognitive decline caused by Alzheimer disease (AD) and other illnesses causing dementia, information is needed from well-characterized individuals without dementia studied longitudinally until autopsy...
  22. pmc Predictors of physician referral for patient recruitment to Alzheimer disease clinical trials
    James E Galvin
    Department of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri 63108, USA
    Alzheimer Dis Assoc Disord 23:352-6. 2009
    ..The majority of dementia patients are first evaluated by community-based physicians; however, physician perceptions of clinical research are largely unknown...
  23. ncbi request reprint Personality traits distinguishing dementia with Lewy bodies from Alzheimer disease
    James E Galvin
    Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
    Neurology 68:1895-901. 2007
    ..To identify personality traits that distinguish dementia with Lewy bodies (DLB) from Alzheimer disease (AD)...
  24. ncbi request reprint Cognitive change in Parkinson disease
    James E Galvin
    Department of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
    Alzheimer Dis Assoc Disord 20:302-10. 2006
    ..This review will examine the clinical, cognitive, neuropsychiatric features of cognitive deficits associated with PD, discuss their pathologic basis and propose avenues for future research...
  25. doi request reprint Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil
    James E Galvin
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    Alzheimer Dis Assoc Disord 22:30-8. 2008
    ..Improved attention may have positive effects on cognitive and functional outcomes for AD patients, although this hypothesis requires further study and validation...
  26. ncbi request reprint Development of a population-based questionnaire to explore psychosocial determinants of screening for memory loss and Alzheimer Disease
    James E Galvin
    Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
    Alzheimer Dis Assoc Disord 20:182-91. 2006
    ....
  27. pmc Potential future neuroprotective therapies for neurodegenerative disorders and stroke
    Rawan Tarawneh
    Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park Avenue, Suite 130, St Louis, MO 63108, USA
    Clin Geriatr Med 26:125-47. 2010
    ..Although most of these therapies are experimental, and require further investigation, a few seem to offer promise...
  28. ncbi request reprint Validity and reliability of the AD8 informant interview in dementia
    James E Galvin
    Departments of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park, Suite 130, St Louis, MO 63108, USA
    Neurology 67:1942-8. 2006
    ..To establish the validity, reliability, and discriminative properties of the AD8, a brief informant interview to detect dementia, in a clinic sample...
  29. pmc Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial
    Joseph F Quinn
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    JAMA 304:1903-11. 2010
    ..Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology...
  30. pmc Distinguishing Alzheimer's disease from other major forms of dementia
    Stella Karantzoulis
    Center of Excellence on Brain Aging and Department of Neurology, New York University Langone Medical Center, NY, USA
    Expert Rev Neurother 11:1579-91. 2011
    ..The combined investigation of cognitive and neurobehavioral symptoms coupled with imaging markers could provide a more accurate approach for differentiating between AD and other major dementia syndromes in the future...
  31. ncbi request reprint Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine
    William J Burke
    Department of Neurology, Saint Louis VAMC and Saint Louis University Health Sciences Center, St Louis, MO 63125, USA
    Acta Neuropathol 115:193-203. 2008
    ..Our findings support the hypothesis that DA metabolism via DOPAL can cause both DA neuron loss and AS aggregation observed in PD...
  32. ncbi request reprint Distinguishing Lewy body dementias from Alzheimer's disease
    Rawan Tarawneh
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63108, USA
    Expert Rev Neurother 7:1499-516. 2007
    ..Improved understanding of disease mechanisms may open new therapeutic avenues for LBD in the future...
  33. ncbi request reprint Neuroanatomical predictors of response to donepezil therapy in patients with dementia
    John G Csernansky
    Alzheimer s Disease Research Center, and Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    Arch Neurol 62:1718-22. 2005
    ..Patients with dementia of the Alzheimer type (DAT) respond variably to treatment with acetylcholinesterase inhibitors...
  34. pmc Persistent short-term memory defects following sleep deprivation in a drosophila model of Parkinson disease
    Laurent Seugnet
    Washington University School of Medicine, St Louis, MO 63110, USA
    Sleep 32:984-92. 2009
    ..Thus we investigated the long-term consequences of sleep deprivation on shortterm memory using a Drosophila model of Parkinson disease...
  35. doi request reprint "Dementia-friendly Hospitals: Care not Crisis": An Educational Program Designed to Improve the Care of the Hospitalized Patient With Dementia
    James E Galvin
    Alzheimer Disease Research Center Departments of Neurology Psychiatry Neurobiology, Washington University School of Medicine Alzheimer Association, St Louis Chapter, St Louis, MO
    Alzheimer Dis Assoc Disord 24:372-9. 2010
    ..2 million hospital stays annually involve a person with dementia, leading to higher costs, longer lengths of stay, and poorer outcomes. Older adults with dementia are vulnerable when hospitals are unable to meet their special needs...
  36. ncbi request reprint Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra
    James E Galvin
    Departments of Neurology, Anatomy and Neurobiology, Alzheimer s Disease Research Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Acta Neuropathol 112:115-26. 2006
    ..In this review, we discuss the role of the DA metabolite 3,4-dihydroxyphenylacetaldehyde to provide a plausible link between DA production and metabolism, AS aggregation and the pathogenesis of PD...
  37. pmc The muscle protein dysferlin accumulates in the Alzheimer brain
    James E Galvin
    Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park, Suite 130, St Louis, MO 63108, USA
    Acta Neuropathol 112:665-71. 2006
    ..In muscle, dysferlin plays a role in the repair of muscle membrane damage. The accumulation of dysferlin in the AD brain may be related to the inability of neurons to repair damage due to A beta deposits accumulating in the AD brain...
  38. ncbi request reprint Dementia with Lewy bodies
    James E Galvin
    Alzheimer s Disease Research Center, Department of Neurology, Washington University School of Medicine, St Louis, MO 63108, USA
    Arch Neurol 60:1332-5. 2003
  39. doi request reprint Curcumin inhibits aggregation of alpha-synuclein
    Neeraj Pandey
    Department of Anatomy and Neurobiology, Washington University School of Medicine, St Louis, MO 63110, USA
    Acta Neuropathol 115:479-89. 2008
    ..Our data suggest that curcumin inhibits AS oligomerization into higher molecular weight aggregates and therefore should be further explored as a potential therapeutic compound for PD and related disorders...
  40. ncbi request reprint Expression profiling and pharmacotherapeutic development in the central nervous system
    James E Galvin
    Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
    Alzheimer Dis Assoc Disord 18:264-9. 2004
    ..This is a difficult task that demands a multidisciplinary approach that is highlighted in this review within the context of neurodegenerative pathology...
  41. ncbi request reprint Neurodegenerative diseases: pathology and the advantage of single-cell profiling
    James E Galvin
    Alzheimer s Disease Research Center, Department of Neurology and Anatomy, Washington University School of Medicine, St Louis, Missouri 63108, USA
    Neurochem Res 29:1041-51. 2004
    ..The pathologic features of neurodegenerative diseases are first discussed followed by a rationale behind sampling mRNA species from single cells rather than from whole-brain homogenates to explore disease mechanisms...